Articles by Ronald A. Rader

1. Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs 5/14/2021

   Manufacturing capacity for both cell therapies and gene therapy viral vectors remains in short supply. From BioPlan Associates, Inc.'s new survey of biopharmaceutical manufacturing professionals, there is a current and worsening capacity crunch. The industry continues to demand innovative solutions from its suppliers in key areas that can be slow to develop. 

2. Changing Perceptions On Bioprocess Intensification, Continuous Processing 3/1/2021

   Process intensification and continuous bioprocessing are concepts with inconsistent definitions. What's included often varies greatly and, in some ways, has become more about aspirational goal-setting than actual innovation adoption. Here, BioPlan Associates assesses the changing perspectives of 122 bioprocess decision-makers.

3. Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19 12/11/2020

   Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.

4. COVID-19's Impact On Bioprocessing: Insights From Industry Leaders 8/5/2020

   We interviewed 26 biopharma senior executives regarding how they are handling the crisis and its long-term impact on their operations. We found the pandemic has begun to catalyze and accelerate a number of significant changes, including many preexisting trends.

5. Biosimilar Pipeline Experiencing 12% Annual Growth: A Progress Update 3/26/2020

   This article compares aspects of the biosimilar development pipeline and related market evolution since 2013, including what has and hasn’t changed.